Latest results from the dose‐expansion part (Part 2) of the Brainshuttle™ AD study of trontinemab in people with Alzheimer’s disease
Results from the completed Cohorts 1-4 in Part 1 of the Brainshuttle™ AD study suggest that early and pronounced effects on several key markers of AD pathophysiology can be achieved with trontinemab treatment with very limited incidence of ARIA.
Authors
- Stella Yilmaz
- David J. Agnew (ORCID: https://orcid.org/0000-0003-0205-8145)
- Fabien Alcaraz
- Silke Ahlers
- Ruth Croney (ORCID: https://orcid.org/0009-0004-8176-3073)
- Luka Kulic (ORCID: https://orcid.org/0000-0003-3427-9436)
- Paul Delmar (ORCID: https://orcid.org/0000-0002-2095-6283)
- Hanno Svoboda (ORCID: https://orcid.org/0009-0005-1910-586X)
- Carsten Hofmann
- Jakub Wojtowicz (ORCID: https://orcid.org/0009-0007-6659-8008)
- Denise Sickert
- Andres Schneider
- Maddalena Marchesi
- Gregory Klein
- Iris Wiesel
- João A. Abrantes
- Stephen Salloway
Institutions
- Roche (Switzerland) (CH)
- Butler Hospital (US)
- Roche (United Kingdom) (GB)
- Excelitas Technologies (Germany) (DE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_104293
- Citations
- 1
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 1.47